Nosocomial pneumonia.ppt
-
Upload
winson-chitra -
Category
Documents
-
view
228 -
download
0
Transcript of Nosocomial pneumonia.ppt
-
7/27/2019 Nosocomial pneumonia.ppt
1/37
Nosocomial Pneumonia
Presented by Ri
-
7/27/2019 Nosocomial pneumonia.ppt
2/37
DefinitionNosocomial pneumonia:
Occurring at least 48 hours after admissionand not incubating at the time ofhospitalization
-
7/27/2019 Nosocomial pneumonia.ppt
3/37
IntroductionNosocomial pneumonia is the 2nd mostcommon hospital-acquired infections after UTI.
Accounting for 31 % of all nosocomial infections
Nosocomial pneumonia is the leading cause ofdeath from hospital-acquired infections.
The incidence of nosocomial pneumonia ishighest in ICU.
-
7/27/2019 Nosocomial pneumonia.ppt
4/37
IntroductionThe incidence of nosocomial pneumonia inventilated patients was 10-fold higher than
non-ventilated patients
The reported crude mortality for HAP is 30%to greater than 70%.
--- Medical Clinics of North AmericaTherapy of Nosocomial pneumonia 2001 vol.85 1583-94
-
7/27/2019 Nosocomial pneumonia.ppt
5/37
Pathogenesis
-
7/27/2019 Nosocomial pneumonia.ppt
6/37
PathogenesisFor pneumonia to occur, at least one of thefollowing three conditions must occur:
1. Significant impairment of host defenses
2. Introduction of a sufficient-size inoculum to overwhelmthe host's lower respiratory tract defenses
3. The introduction of highly virulent organisms into the
lower respiratory tractMost common is microaspiration oforopharyngeal secretions colonized withpathogenic bacteria.
-
7/27/2019 Nosocomial pneumonia.ppt
7/37
Pathogenesis
--- The Prevention of Ventilator-Associated Pneumonia Vol.340 Feb 25, 1999 NEJM
-
7/27/2019 Nosocomial pneumonia.ppt
8/37
ClassificationEarly-onset nosocomial pneumonia:
Occurs during the first 4 days
Usually is due to S. pneumoniae, MSSA, H. Influenza,or anaerobes.
Late-onsetnosocomial pneumonia:
More than 4 days
More commonly by G(-) organisms, esp. P. aeruginosa,
Acinetobacter, Enterobacteriaceae (klebsiella,
Enterobacter, Serratia) or MRSA.
-
7/27/2019 Nosocomial pneumonia.ppt
9/37
Causative AgentEnteric G(-) bacilli are isolated mostfrequently particularly in patients with late-
onset disease and in patients with seriousunderlying disease often already on broad-spectrum antibiotics.
Prior use of broad-spectrum antibiotics andan immunocompromised state make resistantgram-negative organisms more likely.
-
7/27/2019 Nosocomial pneumonia.ppt
10/37
Causative AgentP. aeruginosa andAcinetobacter arecommon causes of late-onset pneumonia,particularly in the ventilated patients.
-
7/27/2019 Nosocomial pneumonia.ppt
11/37
Causative AgentS. aureus is isolated in about 20~40% ofcases and is particularly common in :1. Ventilated patients after head trauma, neurosurgery,
and wound infection2. In patients who had received prior antibiotics or
Prolonged care in ICU
MRSA is seen more commonly in patients
Received corticosteroids
Undergone mechanical ventilation >5 days
Presented with chronic lung disease
Had prior antibiotics therapy
-
7/27/2019 Nosocomial pneumonia.ppt
12/37
Causative AgentAnaerobes are common in patientspredisposed to aspiration
VAP with anaerobes occurred more often withoropharyngeal intubation than nasopharyngealintubation.
-
7/27/2019 Nosocomial pneumonia.ppt
13/37
Causative AgentLegionella pneumophilia occurs sporadically butmay be endemic in hospitals with contaminated watersystems. The incidence is underestimated because the
test to identify Legionella are not performed routinely.
Because the incubation period of Legionella infection is2 to 10 days. cases that occur more than 10 days afteradmission are considered to be nosocomial, and cases
that develop between 4 and 10 days are considered aspossible nosocomial.
Patients who are immunocompromised, critically ill, oron steroids are at highest risk for infection.
-
7/27/2019 Nosocomial pneumonia.ppt
14/37
Ventilator-associated
Pneumonia (VAP)
-
7/27/2019 Nosocomial pneumonia.ppt
15/37
Ventilator-associated
Pneumonia (VAP)Definition:
Nosocomial pneumonia has developed in patient who
are receiving mechanical ventilation
Classification:
Early-onset: within 48-72 hours after tracheal
intubation, which complicates theintubation process
Late-onset: after 72 hours
-
7/27/2019 Nosocomial pneumonia.ppt
16/37
PathogenesisRequire 2 important processes:
1. Bacterial colonization of the aerodigestive tract
2. Aspiration of contaminated secretion into the
Lower airway
Prevents mechanical clearance by cough andthe mucociliary escalator.
-
7/27/2019 Nosocomial pneumonia.ppt
17/37
Prevention for VAPThe oral regimen (topical gentamicin, Colistin,
Vancomycin cream q6h for 3 weeks) treating
oropharyngeal colonization could prevent VAP.
--- Prevention of VAP by oral decontamination
American journal of respiratory critical care medicine2001 164:382-8
-
7/27/2019 Nosocomial pneumonia.ppt
18/37
Preventions for VAPNon-pharmacologic strategies
Effective hand washing and use of protective gowns
and glovesSemirecumbent positioning
Avoidance of large gastric volume
Oral (non-nasal) intubation
Continuous subglottic suctioningHumidification with heat and moisture exchanger
Posture change
--- The Prevention of Ventilator-Associated Pneumonia Vol.340 Feb 25, 1999 NEJM
-
7/27/2019 Nosocomial pneumonia.ppt
19/37
Preventions for VAPPharmacologic strategies
Stress-ulcer prophylaxis
Combination antibiotic therapy
Prophylactic antibiotic therapy
Chlorhexidine oral rinse
Prophylactic treatment of neutropenic pt
Vaccines
--- The Prevention of Ventilator-Associated Pneumonia Vol.340 Feb 25, 1999 NEJM
-
7/27/2019 Nosocomial pneumonia.ppt
20/37
Treatment
-
7/27/2019 Nosocomial pneumonia.ppt
21/37
TreatmentMost initial therapy is empiric because no
pathogen is identified or results are not
available when antimicrobial decisions aremade in most patients.
-
7/27/2019 Nosocomial pneumonia.ppt
22/37
TreatmentInitially be treated with a broad-spectrumantibiotic regimen aimed at covering all
likely bacterial pathogen
This regimen should subsequently benarrowed, according to the result of
culture
-
7/27/2019 Nosocomial pneumonia.ppt
23/37
TreatmentThe pathogen may be influenced bycoexisting illnesses, prior treatment, and
length of hospitalization.
The frequency of ICU-acquired P. Aeruginosacarriage or colonization/infection was 23.4%
at 7 days and 57.8% at 14 days.
---- Current opinion in infectious disease 2002, 15:387-94, copyright LWW
-
7/27/2019 Nosocomial pneumonia.ppt
24/37
TreatmentThe mortality can be reduced with earlyappropriate empiric therapy.(Form 30 % withappropriate therapy to more than 90 % with inappropriate therapy)
Inappropriate initial antibiotic therapy wasassociated with:1. Higher crude hospital mortality (60.7 vs. 47.3%)
2. Longer ICU stay in survivors (20 vs. 12 days)
3. Longer duration of mechanical ventilator
---- Current opinion in infectious disease 2002, 15:387-94, copyright LWW
-
7/27/2019 Nosocomial pneumonia.ppt
25/37
TreatmentGuideline was published in 1996 by Americanthoracic society and separated patients into
three groups, each with a set of probablepathogens.
Group 1: mild to moderate HAP with no risk factor
Group 2: mild to moderate HAP with risk factor
Group 3a: severe HAP, early-onset with no risk factor
Group 3b: severe HAP, late-onset or with risk factor
-
7/27/2019 Nosocomial pneumonia.ppt
26/37
Group 1. & 3a.
(Or 4th cephalosporin, Cefepime)
-
7/27/2019 Nosocomial pneumonia.ppt
27/37
Group 2.
-
7/27/2019 Nosocomial pneumonia.ppt
28/37
Group 3b.
prolonged ICU course
structural lung disease
previous antibiotic use
-
7/27/2019 Nosocomial pneumonia.ppt
29/37
TreatmentFor mild-to-moderate HAP, monotherapy hasbeen shown to be effective.
For severe HAP in which infection withresistant organisms is likely, combinationtherapy probably should be instituted until
culture result are available.
-
7/27/2019 Nosocomial pneumonia.ppt
30/37
TreatmentPatients for S. aureus infection, agents againstthis organism are necessary, including
Vancomycin if MRSA is suspected.
Linezolidis comparable with Vancomycin.
The advantage of Linezolid is less possiblenephrotoxicity
---- current opinion in infectious disease 2002, 15:387-94, copyright LWW
-
7/27/2019 Nosocomial pneumonia.ppt
31/37
TreatmentCombination of antipseudomonal drugs iscontroversial:
1. Traditional:antipseudomonal beta-lactamwith an Aminoglycoside.
Synergy but potential nephrotoxicity.
2. Another approach:
antipseudomonal beta-lactam with a Fluoroquinolone.No benefit of synergy but reduce concern of nephrotoxicity,and quinolone gets into the lungs at higher concentrations.
-
7/27/2019 Nosocomial pneumonia.ppt
32/37
TreatmentResults:
1. Some pathogens, such as H. influenzae, cure
rate is high, and 7 to 10 days is adequate.
2. Highly resistant G(-) organisms(Acinetobacter or
pseudomonas) require prolonged combination
therapy for 21 days.
3. MRSA, requiring prolonged therapy.
-
7/27/2019 Nosocomial pneumonia.ppt
33/37
Response of Therapy
-
7/27/2019 Nosocomial pneumonia.ppt
34/37
Response of TherapyBecause of the delays in clinical response of treatment,it is thought that unless there is significant clinicaldeterioration or new microbiologic information,
therapy should not be changed for at least thefirst 48 to 72 hours
Measured by quantitating the bacterial load in thelower respiratory tract at the initiation of therapy and
several days later.
Bacterial concentrations decreased or no growth -- clinical improvement
Elevated -- experienced clinical failure
-
7/27/2019 Nosocomial pneumonia.ppt
35/37
Response to Therapy
If no clinical response is noted or deterioration occurs,we need to consider:
1. Infectious causes:
Resistant pathogen
Superinfection
Unusual pathogens
Lung abscess
Extrapulmonary infection
2. Noninfectious events:
Heart: CHF
Lung: fibroproliferative ARDS, pulmonary emboli, Atelectasis
-
7/27/2019 Nosocomial pneumonia.ppt
36/37
ReferenceThe prevention of ventilator-associated pneumonia
NEJMvol.340 Feb 25, 1999
Therapy of nosocomial pneumonia
Medical clinics of north America 2001 vol.85 1583-94
Prevention of VAP by oral decontamination
American journal of respiratory critical care medicine 2001 164:382-8
Current opinion in infectious diseaseCopyright LWW 2002, 15:387-94
-
7/27/2019 Nosocomial pneumonia.ppt
37/37
Thanks for Your Attention!!